Bayer, Nuvisan to open small molecule research center

By Jenni Spinner

- Last updated on GMT

(Image: Getty/Gorodenkoff)
(Image: Getty/Gorodenkoff)

Related tags: Bayer, Nuvisan, Germany

The firms are joining forces to establish a specialized research unit in Berlin.

Bayer plans to shift a significant portion of its Berlin-based small molecule research activity to Nuvisan. The latter company provides clinical study, laboratory and contract manufacturing services.

Joerg Moeller, head of research and development for Bayer AG’s Pharmaceuticals Division and member of its executive committee, said the firm hopes to build a “strong, full-fledged research unit​” with Nuvisan.

Nuvisan shares our vision that the new research center can become an important player in research partnering based on the joint know-how and capabilities of our highly qualified scientists​,” Moeller said.

The new research entity housed at the center reportedly will create 400 jobs in the area. Capabilities across the drug discovery chain include lead discovery, medicinal chemistry, pharmacology, drug metabolism and pharmacokinetics, investigational toxicology, and animal management.

Dietrich Bruchmann, Nuvisan CEO and managing partner, said the capabilities of the German facility will empower a “high-performance research team​” by offering access to specialized technology.

The acquisition of the research unit and its location at the Bayer R&D campus will create an operational hub in the scientific excellence cluster in Berlin and allow us to significantly accelerate the drug development process from discovery to clinical trials​,” Bruchmann said.

According to Bayer, the partnership will enable the company to focus its efforts on R&D flexibility and productivity. Bayer intends to continue additional research activities and corporate functions at its Berlin-based Pharmaceuticals Division.

The arrangement marks the latest in a series of partnerships Bayer has formed with other entities in the past few months. In late January 2020, the firm inked a five-year deal with Schrodinger​ to develop molecule-design software. A few weeks earlier, Bayer expanded its work with Evotec​ on developing women’s health drugs.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars